ICU Medical (NASDAQ:ICUI) Updates FY24 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $5.40-5.70 for the period, compared to the consensus estimate of $5.24. ICU Medical also updated its FY 2024 guidance to 5.400-5.700 EPS.

Analyst Ratings Changes

Several analysts recently commented on the stock. KeyCorp increased their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday. StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Wednesday. Raymond James boosted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Stock Down 2.4 %

ICUI stock traded down $4.20 during midday trading on Friday, reaching $167.76. The stock had a trading volume of 37,793 shares, compared to its average volume of 274,538. The company has a current ratio of 2.29, a quick ratio of 1.08 and a debt-to-equity ratio of 0.75. ICU Medical has a 52-week low of $82.82 and a 52-week high of $196.26. The company’s fifty day simple moving average is $176.32 and its 200 day simple moving average is $142.19.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, beating the consensus estimate of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The firm had revenue of $580.07 million during the quarter, compared to the consensus estimate of $574.77 million. Equities analysts expect that ICU Medical will post 3.81 EPS for the current fiscal year.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. This trade represents a 10.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,502 shares of company stock valued at $6,573,496. Corporate insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.